US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.72

+1.072.57%

Post-market: 42.970.2500+0.59%19:59 EDT

Volume:219.40K

Turnover:9.26M

Market Cap:318.26M

PE:- -

High:42.86

Open:41.64

Low:41.44

Close:41.65

52wk High:42.97

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.69

T/O Rate:2.94%

Dividend:0.28

Dividend Rate:0.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Early notable gainers among liquid option names on September 23rd

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633

THOMSON REUTERS

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000

Cboe data suggests bullish flow in Moderna with shares up 5.72%

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

New precision medicine venture gives Syngenis added firepower

The West Australian

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

MT Newswires Live

Moderna up over 7%, on Track for Highest Close Since January 2023

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IDNA/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":42.72,"timestamp":1791230400000,"preClose":41.65,"halted":0,"volume":219396,"hourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"delay":0,"changeRate":0.025690276110444187,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Closed","change":1.07,"latestTime":"10-05 16:00:00 EDT","open":41.64,"high":42.855,"low":41.44,"amount":9262746.200987998,"amplitude":0.033974,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791273600000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":41.65,"sharesOutstanding":5100000,"nav":41.483661,"aum":309297448.94,"dividendRate":0.006538,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":42.28,"preClose":41.65,"latestTime":"08:46 EDT","volume":75,"amount":3191.99985,"timestamp":1791204366525,"change":0.63,"changeRate":0.015126,"amplitude":0.020168},"postHourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"volumeRatio":0.685928,"impliedVol":0.2456,"impliedVolPercentile":0.6932},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.685928,"shares":7450000,"dividePrice":0.2793,"high":42.855,"amplitude":0.033974,"preClose":41.65,"low":41.44,"week52Low":23.9,"pbRate":"--","week52High":42.97,"institutionHeld":0,"latestPrice":42.72,"eps":0,"divideRate":0.006538,"volume":219396,"delay":0,"ttmEps":0,"open":41.64,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.79,"twentyDayClose":39.77,"sixtyDayClose":33.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669948489","title":"Early notable gainers among liquid option names on September 23rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669948489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669948489?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:55","pubTimestamp":1790171726,"startTime":"0","endTime":"0","summary":"Notable gainers among liquid option names this morning include Moderna (MRNA) $191.25 +8.69, Veeva (VEEV) $270.83 +9.92, Palantir Technologies (PLT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/early-notable-gainers-among-liquid-option-names-on-september-23rd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/early-notable-gainers-among-liquid-option-names-on-september-23rd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261372.USD","IE00B19Z9Z06.USD","BK4613","PLTZ","PLTD","PLTA","LU0170899867.USD","BK4528","BK4167","PLTL","PTIR","LU1861558580.USD","BK4534","LU1989764748.USD","BK4547","LU0058720904.USD","PLTW","LU0289739699.SGD","LGHT","IDNA","AIPI","EKG","LU1989764664.SGD","GNOM","PLTG","PLTR","BK4023","BK4568","MRNY","PLTI","IE00BZ9MQY76.HKD","LU1861559042.SGD","PLYY","BK4139","BK4504","LU0006306889.USD","PLTY","SHLD","BK4501","BK4585","WDNA","VEEV","EYES","GUNZ","PLOO","BK4551","MRNX","BK4532","IE00B894F039.SGD","BK4543","PLT","BK4548","MRNA","BK4588","SPLTRmain","LU0266013472.USD","PLTU","BK4533","IGV","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669648508","title":"Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669648508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669648508?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:30","pubTimestamp":1790166641,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-vertex-pharmaceuticals-vrtx-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-vertex-pharmaceuticals-vrtx-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","IE00B894F039.SGD","BK4533","IBBQ","LU2089984988.USD","LU2237438978.USD","BIB","XBI","LU0432979614.USD","NKTR","XLV","HCSG","VERX","LU0234570918.USD","LU1674673428.USD","LU1559883803.SGD","LU2324357040.USD","BK4585","IE00BZ9MQY76.HKD","BK4007","IE0002141913.USD","LU1069344957.HKD","GNMX","LU0289739699.SGD","BBH","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","IE0002270589.USD","LABU","LU0109394709.USD","SG9999001176.SGD","BK4139","LU0757428866.USD","LU0823416689.USD","LU2417539215.USD","KYMR","BK4023","LU0417517546.SGD","IDNA","SG9999001176.USD","LU2362541513.USD","PBE","IE00BJJMRZ35.SGD","VRTX","LU0256863811.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882944","title":"Wave Life Sciences initiates Phase 2a combination trial of WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882944?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:35","pubTimestamp":1790163326,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combinatio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","WVE","HYLG","MEDX","GDOC","BK4007","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711101","title":"Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669711101?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:10","pubTimestamp":1790154626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quest Diagnostics (DGX), AnaptysBio (ANAB) and Verte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quest-diagnostics-dgx-anaptysbio-anab-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quest-diagnostics-dgx-anaptysbio-anab-and-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANAB","IE0002270589.USD","LU2506951875.HKD","FFTY","SG9999001176.USD","LU2456880835.USD","VERX","LU0109394709.USD","LU0823417737.USD","IBB","LU1093756325.SGD","LU1854103824.USD","BK4139","LU0079474960.USD","IDNA","SG9999001176.SGD","IE00BJT1NW94.SGD","LU1815336091.USD","TBXU","BK4583","LU2089984988.USD","VRTX","IBBQ","LU1035775433.USD","BK4567","LU0417517546.SGD","BIB","XLV","GNMX","SGXZ57979304.SGD","LU0757428866.USD","IE00BZ9MQY76.HKD","LU2506952170.USD","LU0289739699.SGD","LU2506952097.USD","XBI","IE0009355771.USD","LABU","LU0234570918.USD","IE00B2B36J28.USD","LU1585245621.USD","PBE","LU0823417653.USD","LU0823416689.USD","BBH","DGX","IE00B19Z3B42.SGD","LU2462157665.USD","HCSG","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177094","title":"These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177094?lang=en_us&edition=fundamental","pubTime":"2026-09-23 13:45","pubTimestamp":1790142300,"startTime":"0","endTime":"0","summary":"From speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has ri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4551","IE00B3S45H60.SGD","LU0795875169.SGD","LU1989772840.SGD","LU0210528500.USD","MRNY","LU1244550221.USD","BK4585","IE00BKVL7J92.USD","LU0098860793.USD","LU0006306889.USD","LU1244550494.USD","BK4534","LU1548497426.USD","MS","IAI","LGHT","LU1074936037.SGD","TBXU","BK4504","LU1732800096.USD","BK4548","LU1791710582.SGD","BK4568","BK4532","LU0158827948.USD","IBB","ARWR","LU1720051017.SGD","OZEM","BK4501","XBI","LU2347655156.SGD","THNR","GNOM","MRNA","VKTX","IE00B4R5TH58.HKD","IE00B775SV38.USD","FMED","LU1988902786.USD","ARGX","KBWB","BK4599","MRNX","WDNA","LU2357305700.SGD","LU0109394709.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669999174","title":"Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633","url":"https://stock-news.laohu8.com/highlight/detail?id=2669999174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669999174?lang=en_us&edition=fundamental","pubTime":"2026-09-23 11:36","pubTimestamp":1790134588,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU1585245621.USD","BK4585","LU2362540622.SGD","SG9999013999.USD","IE0002141913.USD","LU0109394709.USD","LU1035775433.USD","GNMX","IE00B2B36J28.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU2237438978.USD","VRTX","LU0432979614.USD","IDNA","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","BBH","LU1778281490.HKD","BK4588","LU2362541273.HKD","LU0234570918.USD","IE00B19Z9P08.USD","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z9Z06.USD","BIB","IE0009355771.USD","PBE","TBXU","LU2417539215.USD","IBBQ","LU0061475181.USD","LU0058720904.USD","BK4567","LU2456880835.USD","SG9999001176.USD","LU1674673428.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","BK4139","IE00BZ9MQY76.HKD","LU1093756325.SGD","IE00B894F039.SGD","LU1093756168.USD","LU1069344957.HKD","IBB","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669120310","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2669120310","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669120310?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:00","pubTimestamp":1790114446,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $347,000Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sold 1,7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL64Mcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","BBH","BK4139","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","PTH","IE0009354923.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","CANC","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669312925","title":"Cboe data suggests bullish flow in Moderna with shares up 5.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669312925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669312925?lang=en_us&edition=fundamental","pubTime":"2026-09-23 01:45","pubTimestamp":1790099113,"startTime":"0","endTime":"0","summary":"Cboe data suggests bullish flow in Moderna (MRNA), with shares up $9.88, or 5.72%, near $182.82. Options volume running well above average with 200...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-suggests-bullish-flow-in-moderna-with-shares-up-5-72-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-suggests-bullish-flow-in-moderna-with-shares-up-5-72-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4585","BK4501","GNOM","LGHT","BK4532","BK4139","BK4548","BK4588","MRNA","MRNX","MRNY","IDNA","WDNA","BK4551","BK4568","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","LU0234570918.USD","LU1559883803.SGD","VERX","VRTX","BBH","GNMX","IE00BFTCPJ56.SGD","LU2237438978.USD","LU0079474960.USD","LU0256863811.USD","PBE","IE00B894F039.SGD","BK4585","LU1093756168.USD","LU0432979614.USD","LU2324357040.USD","MAZE","IBB","LU0289739699.SGD","LU1674673428.USD","LU1069344957.HKD","LU2236285917.USD","IE0002141913.USD","IBBQ","IE00B19Z3581.USD","TBXU","LU1585245621.USD","BK4567","LU2089984988.USD","LU1815336091.USD","LU1778281490.HKD","IE00BZ9MQY76.HKD","LU0058720904.USD","SGXZ57979304.SGD","XBI","IE00BJT1NW94.SGD","BK4532","BIB","IDNA","LU2462157665.USD","BK4023","LU2362541513.USD","BK4588","LU1035775433.USD","LU1430594728.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["WDNA","XKO.AU","GNOM","BEAR.AU","E200.AU","EES","OZF.AU","IMLC.AU","JDOC","PBE","XAO.AU","HTEC","ADHD","IDNA","STW.AU","MEDX","IISV.AU","QRE.AU","EIGA.AU","GEAR.AU","BMED","OZR.AU","XT","GIVE.AU","SLF.AU","BK4588","IOZ.AU","ZYAU.AU","GNMX","SYNB","BBOZ.AU","HELX","IBB","LFSC","XJO.AU","DACE.AU","QFN.AU","BK4585","VAP.AU","FDIF","IIGF.AU","VAS.AU","TMAT","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669591125","title":"S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2669591125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669591125?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:00","pubTimestamp":1790092809,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500.SPXTop PerformersPercent ChangeMonolithic Power Systems IncMPWR.OQ+7.8%AutoZone, Inc.AZO.N+6.1%SanDisk CorporationSNDK.OQ+5.8%Moderna, Inc.MRNA.OQ+5.7%O'Reilly Automotive, Inc.ORLY.OQ+4.4%Bottom PerformersPercent ChangeGen Digital Inc.GEN.OQ-6.4%Allstate CorpALL.N-6.1%The Charles Schwab CorporationSCHW.N-6.0%Expedia Group, Inc.EXPE.OQ-5.8%Cisco Systems IncCSCO.OQ-5.5%As of 12:00 p.m., the S&P 500.SPXlost 3.60 points, or 0.05%, to 7,761.10 and had posted 8 new 52-week highs and 10 new lows.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL8N45E192:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","HIBL","LU1934455194.USD","SG9999015952.SGD","AIQ","IJH","BK4525","IAK","SG9999015978.USD","LU1244550221.USD","LU2237443895.HKD","LU0980610538.SGD","MPWC","NOBL","GNOM","SNDC","BK4589","LU2102340556.USD","LU0265550946.USD","LU0053666078.USD","MRNY","LU2462157665.USD","SPYD","LU2463526074.USD","SCHM","LU1880398554.USD","IE00BZ1G4Q59.USD","SG9999015945.SGD","BK4515","IE00B42XCP33.USD","LU0823417653.USD","LU0265550359.USD","BK4141","BK4170","IJR","LU2250418816.HKD","LU0868494617.USD","LU2506952170.USD","LU1116320901.HKD","LU1674673691.USD","SPYM","CIBR","IE00BVYPNW00.USD","CSCL","LU0868494708.USD","LU1037948541.HKD","VTI","LU1201861249.SGD","LU0234572021.USD","SPYH","LU0742534661.SGD","MOAT","LU1244550577.SGD","LU2237443622.USD","LU2417539215.USD","UPRO","LU0823417737.USD","LU1868836591.USD","LU1571399168.USD","LU0251142724.SGD","LU0348723411.USD","LU0098860793.USD","IE000F7OJYX1.SGD","SPHD","HIBS","COWG","IE00BN0W2W23.USD","LU1868836757.USD","LU0234570918.USD","LU1363072403.SGD","LU0353189680.USD","LU0792757196.USD","LU0889566641.SGD","SPYQ","LU0985320562.USD","BK4548","LU0963586101.USD","LU1934455863.HKD","LU1267930573.SGD","CNAV","LU2381873111.SGD","BK4501","MPWX","BK4585","SCHB","LU2355687059.USD","LU2543165471.USD","LU1868836914.USD","LU2089985449.USD","LU1861215975.USD","LU0345770308.USD","MPWR","RSPN","SG9999014039.USD","LU2473716301.USD","LU1852331112.SGD","IE000M9KFDE8.USD",".SPX","BK4533","LU0274383776.USD","LU0965509283.SGD","BK4560","MRNA","SPHQ","LU1069347547.HKD","BK4142","IVV","SG9999014013.SGD","BK4020","BK4504","LU0648001328.SGD","LU2247934214.USD","IVW","LU1235294995.USD","FSMD","LU1074936037.SGD","LU0965508806.USD","IVE","LU1883839398.USD","SPLV","LU1244550494.USD","IE00B3PB1722.GBP","CSCS","PTF","LU0208291251.USD","LU1116320737.USD","LU0029864427.USD","BK4581","LU1430594728.SGD","LU2322448957.HKD","LU2360107671.USD","LU0731783394.SGD","LU2456880835.USD","LU1988902786.USD","LU2236285917.USD","LU0708994859.HKD","LU1032955483.USD","LU0310800379.SGD","PEJ","YSPY","IE00BFMHRM44.USD","SCHW","SDS","LU1699723380.USD","LU0314106906.USD","IE00BN0W2T93.GBP","LU0965509101.SGD","LU1599440770.SGD","LU0942090050.USD","VTV","VOO","LU1823568750.SGD","BMAY","DBSC","CSCO","SFY","LU0251131958.USD","SPXS","LU2237443465.HKD","LU1221951129.SGD","LU0011850046.USD","LU2290526834.HKD","WDNA","IE000SO60NU8.SGD","SG9999001440.SGD","IE000WAW04H5.SGD","LU2506951958.HKD","SH","IE0000B7K699.USD","SPYG","XYLD","SNDU","BK4550","IE00BDGV0183.EUR","IAI","LU0096364046.USD","LU1196500208.SGD","IE00BKVL7J92.USD","IE00BVYPNV92.GBP","DISK","LU0345774391.USD","FCUS","IDNA","LU1267930730.SGD","LU2237443978.SGD","LU1066051811.HKD","LU0353189763.USD","LU2272731782.SGD","SPXU","BK4612","GPIX","LU2286300806.USD","LU1992135399.USD","LU0950375773.USD","LU1934455277.USD","TSPY","LU2506951875.HKD","GSLC","LU2237443549.SGD","SPUS","IE00B7SZLL34.SGD","AWAY","LU2322448791.USD","LU1221951046.USD","SPYU","BK4568","LU0081259029.USD","LU1778281490.HKD","LU0106831901.USD","LU0477156953.USD","LU0056508442.USD","LU1674673428.USD","LU1059921491.USD","DMAX","IE00BFXG0V08.USD","SNDK","RSP","LU0061475181.USD","LU2237443382.USD","LU0128525929.USD","LU1236620834.HKD","LU1868837300.USD","LU1929549753.HKD","LU1585245621.USD","BK4588","LU1046421795.USD","SPGP","LU1861220207.SGD","VOOG","LU1880398471.USD","VBK","ITOT","IE00B1BXHZ80.USD","VV","ACWI","ORLY","LU1791807156.HKD","HK0000819398.USD","LU0070302665.USD","LU1506573853.SGD","EXPE","LU1894683348.USD","OPTZ","IE00B5TLWC47.USD","BK4551","SPY","LU1066053197.SGD","LGHT","BK4127","LU2108987350.USD","LU1037948897.HKD","SCHA","SG9999001077.SGD","IE00BFXG1179.USD","SSO","LU0130102774.USD","IYZ","SG9999002232.USD","IE00BYQQ9H92.USD","JEPI","SMAX","LU0170899867.USD","SNDG","LU0640476718.USD","SPXL","GEN","LU1868837136.USD","LU1064131342.USD","IE00BD6J9T35.USD","04333","LU0345770993.USD","LU1066051498.USD","BK4097","LU1236620750.USD","IE000MB6IJN5.SGD","LU1066051225.USD","LU0708995401.HKD","LU0971096721.USD","LU0048573561.USD","SPUU","BK4214","MMAX","SPDN","IE00BN0W2V16.EUR","ALLW","SG9999002224.SGD","ETFT","LU2931357623.SGD","LU2272731865.HKD","LU0345774631.USD","LU0130517989.USD","IE00B19Z3B42.SGD","XDTE","LU0203345920.USD","RSPU","BK4139","LU2506952097.USD","LU2063271972.USD","IE00B3T34201.USD","LU1267930813.SGD","LU0054578231.USD","LU0320765646.SGD","SG9999001424.SGD","BK4527","SPYV","LU1035773651.USD","ALL","QQQG","AZO","LU1992135472.HKD","TMSL","LU2264538146.SGD","XLG","BK4534","LU1280957306.USD","LU1894683264.USD","IE00B19Z3581.USD","SG9999014021.USD","BK4532","LU2272731600.USD","SNXX","LU0109391861.USD","VEU","LU0203347892.USD","LU1861217088.USD","LU0320765059.SGD","BK4579","LU1153585028.USD","SPMO","LU1162221912.USD","SCHX","SNDQ","IE00BSNM7G36.USD","RSPA","LU0672654240.SGD","IE0002270589.USD","LU1861220033.SGD","LU2360106780.USD","LU0266013472.USD","LU2360107168.USD","LU2087625088.SGD","BK4107","MRNX","IE00BGHQF631.EUR","SG9999015986.USD","LU1668664300.SGD","IE000BZT7R73.USD","SG9999014005.SGD","LU0861579265.USD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123074","title":"Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123074","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123074?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:45","pubTimestamp":1790091909,"startTime":"0","endTime":"0","summary":"Incyte's  colorectal cancer or CRC programs remain \"risky and more long-term,\" RBC Capital Markets said in a Tuesday note, while expectations for upcoming pancreatic cancer data remain elevated.The company is set to present data on its oncology programs at the upcoming European Society for Medical Oncology or ESMO Congress, with investors expecting improved efficacy from its '734 KRAS G12D inhibitor. Incyte is evaluating '734 in CRC and pancreatic ductal adenocarcinoma or PDAC, while its '890 program is being studied in CRC, according to the note.For PDAC, RBC expects overall response rates or ORR to exceed 80%, compared with 82% for rival zoldonrasib, while the brokerage said the two therapies have appeared comparable on efficacy and that safety could be a differentiating factor longer term.In CRC, RBC said its KOL feedback suggests ORR could range from 45% to 70%, while an ORR in the 80s would be needed to give the community greater comfort in eventual translation to survival.RBC has","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","BK4550","IDNA","INCY","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123650","title":"Moderna up over 7%, on Track for Highest Close Since January 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123650","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123650?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:12","pubTimestamp":1790089920,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  is currently at $186.54, up $13.60 or 7.86%--Would be highest close since Jan. 27, 2023, when it closed at $189.35--On pace for largest percent increase since Sept. 21, 2026, when it rose 12.27%--Currently up four of the past five days--Currently up two consecutive days; up 21.1% over this period--Best two day stretch since the two days ending Aug. 20, 2026, when it rose 111.75%--Up 32.92% month-to-date--Up 532.55% year-to-date--Down 61.5% from its all-time closing high of $484.47 on Aug. 9, 2021--Up 623.3% from 52 weeks ago , when it closed at $25.79--Would be a new 52-week closing high--Up 734.26% from its 52-week closing low of $22.36 on Nov. 20, 2025--Traded as high as $187.19; highest intraday level since Jan. 30, 2023, when it hit $187.59--Up 8.24% at today's intraday high--Best performer in the S&P 500 todayAll data as of 11:09:38 AM ETSource: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MRNX","BK4139","BK4585","BK4501","LGHT","MRNY","BK4588","WDNA","BK4548","BK4568","BK4534","BK4533","GNOM","MRNA","BK4551","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU1559883803.SGD","LU1674673428.USD","IDNA","IE00B19Z3581.USD","BK4585","VERX","LU1093756325.SGD","LU1674673691.USD","LU2456880835.USD","TBXU","LU2362541513.USD","IE0002270589.USD","IE00B4R5TH58.HKD","IBB","BK4532","LU0256863811.USD","LU1093756168.USD","LU1035775433.USD","LU2089984988.USD","SGXZ57979304.SGD","IE0002141913.USD","LU1069344957.HKD","IE0009355771.USD","LU0823416689.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","PBE","BK4023","BBH","GNMX","IE00B894F039.SGD","BIB","LU0079474960.USD","LU2362540622.SGD","LU0889565916.HKD","LU0289739699.SGD","BK4533","VRTX","IE00B19Z3B42.SGD","LU1585245621.USD","SG9999013999.USD","LU0320765992.SGD","IE00B19Z9P08.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0757428866.USD","IBBQ","IE00B19Z9Z06.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00B894F039.SGD","IE00BJT1NW94.SGD","BIB","LU2456880835.USD","IE00BFTCPJ56.SGD","LU2462157665.USD","IE0002270589.USD","LU1585245621.USD","LU2362541273.HKD","VERX","BBH","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","BK4023","LU1778281490.HKD","LU0289739699.SGD","LU1559883803.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","BK4533","LU0432979614.USD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","SGXZ57979304.SGD","VRTX","IE0002141913.USD","LU2236285917.USD","IE0009355771.USD","IE00BZ9MQY76.HKD","TBXU","LU1815336091.USD","LU1674673428.USD","LU0109394709.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669610140","title":"Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669610140?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:58","pubTimestamp":1790085506,"startTime":"0","endTime":"0","summary":"Viking Therapeutics stock rallied more than 32% on Tuesday following a clinical trial update for weight loss drug VK2735.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VKTX","HYLG","THNR","BK4585","BK4139","MEDX","GDOC","NVIB","IDNA","BK4599","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669472461","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669472461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669472461?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:30","pubTimestamp":1790083809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lill...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pyxis-oncology-pyxs-moderna-mrna-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pyxis-oncology-pyxs-moderna-mrna-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0203201768.USD","LU2213496289.HKD","SG9999014914.USD","LU1551013425.SGD","MEDX","LU2552382058.USD","BK4581","LU2106854487.HKD","IE00BK4W5L77.USD","HRTS","LU0238689110.USD","LU1061106388.HKD","LU0203202063.USD","SG9999018857.SGD","MRNX","LU2271345857.HKD","LU2108987350.USD","LU0882574139.USD","LU0385154629.USD","LU1069344957.HKD","LU1267930730.SGD","IE00BN29S564.USD","LU1232071149.USD","LLYX","OZEM","LU2063271972.USD","LU1127390331.HKD","LU0354030511.USD","LU1064131342.USD","LU2168563687.JPY","LU0640476718.USD","LU2168564149.EUR","LU2237443465.HKD","LU0061475181.USD","LU2265009873.SGD","ELIS","IE00B1XK9C88.USD","LU0471298694.HKD","LU2462591350.SGD","PYXS","PPH","LU2023250330.USD","LU1868836757.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","LU0417517546.SGD","LU2237438978.USD","SG9999013999.USD","IE0002141913.USD","LU0786609619.USD","LU2112291526.USD","LU1868837136.USD","LU1814569148.SGD","LU2552382132.HKD","LU1712237335.SGD","FTXH","CANC","IE0004445015.USD","LU2168564222.USD","LU2468319806.SGD","BK4548","IE00BJT1NW94.SGD","SGXZ51526630.SGD","LU2491050154.USD","VHT","BK4532","LU0345770993.USD","LU0345770308.USD","SGXZ81514606.USD","LU0689472784.USD","GDOC","IE00B7KXQ091.USD","SG9999015986.USD","LU1548497426.USD","BK4568","LU2111349929.HKD","IE00BFSS7M15.SGD","LU0225283273.USD","LU0823434740.USD","SG9999018865.SGD","LU2324357040.USD","LU2417539215.USD","RXL","IXJ","LU2602419157.SGD","LU1280957306.USD","ELIL","MRNY","LU0466842654.USD","SGXZ31699556.SGD","LLYZ","LU1691799644.USD","LU0708995401.HKD","LU2023250504.SGD","LU0256863811.USD","LU0256863902.USD","CURE","LU0672654240.SGD","LU2746668461.USD","SG9999015945.SGD","LU1093756168.USD","LU2089283258.USD","LU2023251221.USD","IE0005OL40V9.USD","LU0964807845.USD","LU0823434583.USD","LU0432979614.USD","LU1720051108.HKD","LU0058720904.USD","LU0943347566.SGD","BK4533","SG9999014906.USD","IE00BJJMRY28.SGD","LU0354030438.USD","LU1323610961.USD","LU2491050071.SGD","BK4588","LU2028103732.USD","SGXZ99366536.SGD","WDNA","LU0158827948.USD","LU0174119429.USD","LU1291159041.SGD","LU0094547139.USD","IE00BFSS8Q28.SGD","LU0471298777.SGD","LU0109394709.USD","LU1988902786.USD","TRUH","LU0198837287.USD","LU1868837300.USD","LU1366192091.USD","LU2461242641.AUD","IE00B1BXHZ80.USD","LU0210536198.USD","LU2361044865.SGD","SGXZ57979304.SGD","BK4599","LU0133085943.USD","LGHT","FHLC","LU0122379950.USD","LU0114720955.EUR","LU1989771016.USD","IE00B4R5TH58.HKD","LU2360106947.USD","LU2462157665.USD","TMED","LU2237443622.USD","LU2211815571.USD","LU1623119135.USD","LU2089284900.SGD","LU2552382215.SGD","LU2361045086.USD","MHIP","IE00B2B36J28.USD","SG9999015952.SGD","SG9999017495.SGD","SG9999001176.SGD","LU0353189763.USD","LU0096364046.USD","LU0823416689.USD","LU1979441026.SGD","PJP","IE00BWXC8680.SGD","LU0289739699.SGD","LU0316494557.USD","LU2456880835.USD","IE00BKPKM429.USD","SG9999014898.SGD","BK4534","BK4139","LU2896262040.SGD","MEDI","IE0004445239.USD","LU0097036916.USD","IE00B775H168.HKD","LU2471134879.HKD","LU2471134952.CNY","LU0456855351.SGD","LU0266013472.USD","IE0009355771.USD","GNOM","AGNG","LU2237443549.SGD","BK4007","GB00BDT5M118.USD","LU0079474960.USD","LU1917777945.USD","LU0006306889.USD","IE00BJJMRX11.SGD","LU1974910355.USD","LU2237443895.HKD","LU2491049909.HKD","MRNA","LU1868836591.USD","LU2264538146.SGD","IE0001KFT4U8.USD","LLII","LU0323591593.USD","LU2087625088.SGD","LU0882574055.USD","IE00BK4W5M84.HKD","IHE","LU2471134796.USD","LU0106261372.USD","LU0109391861.USD","LU0320765992.SGD","LU0820562030.AUD","LU0889565916.HKD","LU2089984988.USD","BK4501","BK4585","LU0320765059.SGD","ILDR","LU1023059063.AUD","LU2357305700.SGD","LU0158827781.USD","LU2750360641.GBP","LU1629891620.HKD","THNR","LU0683600562.USD","LU2746668974.SGD","SG9999001176.USD","LU1551013342.USD","SG9999015978.USD","LU2236285917.USD","LU2756315318.SGD","LU2168564495.EUR","BK4551","IDNA","IE00BJLML261.HKD","LU0820561909.HKD","BK4516","JDOC","LLY","LU0820561818.USD","LU1145028129.USD","LU1804176565.USD","IYH","IE00BKDWB100.SGD","LU2237443382.USD","LU0234572021.USD","LU2471134523.USD","SG9999014880.SGD","LU0353189680.USD","LU1035775433.USD","LU1057294990.SGD","LU1720051017.SGD","LU1983299246.USD","LU2361044949.HKD","LU2750360997.AUD","LU2237443978.SGD","IE00B4JS1V06.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU0787776722.HKD","LU2168564065.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0256863811.USD","GNMX","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2362541513.USD","LU0079474960.USD","PBE","SG9999013999.USD","LU2089984988.USD","LU2362540622.SGD","LU2417539215.USD","LU0417517546.SGD","IE0009355771.USD","BK4533","BK4567","BK4585","LU1093756325.SGD","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","IE00B19Z9P08.USD","LU0823416689.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","VRTX","LU0234570918.USD","IDNA","IBB","LU2236285917.USD","LU2362541273.HKD","BK4588","LU0432979614.USD","LU1093756168.USD","SG9999001176.SGD","BBH","IE0002141913.USD","LU2237438978.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","LU1674673691.USD","IE00B894F039.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669739142","title":"Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669739142","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669739142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (\"Optimi\" or the \"Company\"), a commercial-stage pharmaceutical manufacturer of","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","IDNA","MEDX","OPTH","HYLG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142210","title":"AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142210?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081700,"startTime":"0","endTime":"0","summary":"Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have h","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366375/29489/en/aim-immunotech-highlights-ampligen-s-potential-role-in-the-evolving-pancreatic-cancer-treatment-landscape-following-fda-approval-of-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BBH","IE00BJJMRZ35.SGD","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","IDNA","LU0109394709.USD","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009354923.USD","CANC","LABU","BK4139","PTH","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}